dibekacin

Dibekacin is a semisynthetic aminoglycoside antibiotic derived from kanamycin B. It acts by binding to the 30S and 50S subunits of bacterial ribosomes, inhibiting protein synthesis and causing errors in genetic code transcription that lead to bacterial cell death. Dibekacin is effective against gram-negative aerobes and some strains of Staphylococci, including those resistant to kanamycin. It is primarily used for severe infections caused by susceptible bacteria and has been marketed mainly in Japan. The drug is administered parenterally (intramuscularly or intravenously) for systemic infections[1][2][3][4].

Brand names

PanamicinDibekacin Meiji

Other names

dibekacinadibekacinedibekacinum